Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KarXT compared to a placebo in treating psychosis linked to Alzheimers Disease. This Phase 3 outpatient study lasts 38 weeks and aims to prevent relapse of psychosis symptoms in affected adults aged 55 to 90. The trial also looks at how long participants stay on treatment without relapse or stopping for any reason, along with monitoring safety and tolerability. Participants are randomly assigned to receive either KarXT capsules in varying doses or placebo capsules. The treatment is administered three times a day during the study period. This double-blind trial ensures neither participants nor researchers know which treatment is given. The study is conducted at multiple centers and includes a placebo control to compare outcomes. Throughout the 38 weeks, participants will attend regular visits for assessments including cognitive tests like the Mini-Mental State Examination, evaluations of psychosis severity, caregiver-reported measures, and safety monitoring such as laboratory tests, vital signs, and adverse event tracking. Researchers will measure the time to relapse and treatment discontinuation, along with side effects and other health indicators. The study is sponsored by Karuna Therapeutics, a Bristol Myers Squibb company.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of masitinib combined with riluzole compared to a placebo combined with riluzole for treating Amyotrophic Lateral Sclerosis ALS. This phase 3 study focuses on patients diagnosed with probable or definite ALS, aiming to understand how masitinib, a drug that targets cells involved in neuroinflammation, might slow disease progression and affect the nervous systems environment. Participants receive oral masitinib at 3.0 mgkgday twice daily, with dose increases to 4.5 mgkgday after 4 weeks, and for some, an additional increase to 6.0 mgkgday after another 4 weeks. Each dose increase includes safety monitoring. Masitinib is given alongside riluzole, a standard ALS treatment at 50 mg twice daily. The control group receives a matching placebo with riluzole. The study is randomized, double-blind, and includes two different masitinib dose escalation schedules. During the 48-week study period, participants undergo regular assessments including functional rating scales ALSFRS-R, quality of life questionnaires ALSAQ-40, survival and progression monitoring, lung function tests FVC, and muscle strength measurements HHD. Researchers measure changes in combined function and survival scores. Safety is closely monitored throughout, with follow-up extending up to 36 months for disease progression or death. Total participation includes baseline screening, treatment, and long-term observation.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
Actively Recruiting
Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are conducting a Phase 3 global, multicenter, 52-week open-label extension study to assess the long-term safety and tolerability of KarXT in people with psychosis associated with Alzheimers Disease. This study includes participants who have completed prior related studies, allowing continued evaluation of this treatment over an extended period. Participants receive KarXT capsules in various doses ranging from 202 mg to 66.76.67 mg three times daily. This extension study follows completion of earlier trials and continues treatment for up to 52 weeks to monitor long-term effects and safety. During the study, participants are monitored for treatment-emergent adverse events from the initial dose through 14 days after the last dose, totaling up to 54 weeks. Researchers track serious adverse events and withdrawals due to adverse events. The involvement lasts approximately one year, focusing on safety and tolerability assessments.
Actively Recruiting
This research aims to collect and analyze clinical activity and management data from Orthogeriatrics and Orthopedics Units treating geriatric patients with hip fractures. By continuously gathering data over a long period, the study seeks to compare how different centers manage care and to guide improvements in clinical practice within orthogeriatrics. The study is a multicenter, prospective observational cohort study enrolling an estimated 7,000 patients aged 65 and older over five years. Data collection can be done either continuously with high intensity on all new cases or yearly with low intensity involving a smaller set of variables over one month. Centers voluntarily choose their preferred data collection method. Participants will be followed for 120 days after enrollment, with an additional four months allowed for the last patients to complete follow-up. Researchers will collect clinical data to assess management approaches, track fracture patterns and patient profiles by age, and evaluate improvements in clinical practice and interdisciplinary collaboration. The study will run for approximately five years and monitor outcomes related to orthogeriatric care models and sensitivity to elderly patient needs.
Actively Recruiting
Researchers are studying patients with Severe Acquired Brain Injuries to identify medium-term factors that can predict important recovery milestones. They aim to understand how these factors affect outcomes and to develop a system that continuously assesses the quality of care in rehabilitation units. This observational study collects data from patients admitted to specialized rehabilitation units within 14 weeks after their brain injury. Data collected includes structural and organizational information about the rehabilitation units, detailed patient information at admission, and follow-up evaluations four months after the acute brain injury. The study focuses on predicting key rehabilitation outcomes such as removal of tracheostomy tubes, control of the trunk, and ability to eat entirely by mouth. These outcomes are assessed during the four months following the injury. Participants undergo evaluations at admission and again four months later. Researchers collect clinical and organizational data to analyze patient progress and quality of care. The main outcomes measured are tracheostomy tube status, trunk control, and total feeding by mouth, tracked from July 2021 to June 2025. The study will continue data collection and analysis through June 2027.